Search clinical trials for: ALIROCUMAB+SAR236553+%28REGN727%29

Total 47 results

Regeneron Pharmaceuticals
Sanofi

Terminated

Long Term Safety Study of PRALUENT

Heterozygous Familial Hypercholesterolemia | Non-familial Hypercholesterolemia

United States, Bulgaria, Estonia, Russian Federation, South Africa, Ukraine
Regeneron Pharmaceuticals
Sanofi

Terminated

Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (ODYSSEY ESCAPE)

Heterozygous Familial Hypercholesterolemia

United States, Germany
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Hypercholesterolemia

France, United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ODYSSEY HoFH)

Homozygous Familial Hypercholesterolemia

United States, South Africa, Canada, Greece, Japan, Ukraine, Austria, Czechia, France, Germany, Italy, Taiwan, Turkey
Sanofi
Regeneron Pharmaceuticals

Completed

Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects

Hypercholesterolemia

United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects

Hypercholesterolemia

Moldova, Republic of, France
Sanofi
Regeneron Pharmaceuticals

Completed

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Hypercholesterolemia

China
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

Hypercholesterolemia

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Atherosclerotic Cardiovascular Disease

China, Hong Kong, Austria, Bulgaria, Norway, Peru, France, Japan, Spain, Lithuania, Philippines, Israel, Belgium, Croatia, Poland, Hungary, Chile, Mexico, Latvia, Singapore, Switzerland, Colombia, Greece, Ukraine, Turkey, Finland, United States and more
Regeneron Pharmaceuticals
Sanofi

Completed

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Open Label Study of Long Term Safety Evaluation of Alirocumab (ODYSSEY OLE)

Hypercholesterolemia

United States, Argentina, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, United...
Sanofi
Regeneron Pharmaceuticals

Completed

Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Hypercholesterolemia

United States, Bulgaria, Canada, Norway, Israel, Slovakia, United Kingdom, Hungary
Sanofi
Regeneron Pharmaceuticals

Completed

Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Hypercholesterolemia

Korea, Republic of, Taiwan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Hypercholesterolaemia

Netherlands, United States, Canada, Russian Federation, South Africa
Sanofi
Regeneron Pharmaceuticals

Completed

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Hypercholesterolemia

Sweden, Germany, Russian Federation, Denmark, Israel, South Africa, Spain, Hungary, United States, Colombia, Czech Republic, Argentina, Belgium, Bulgaria, Canada, Chile, Finland, France, Italy, Mexico, Netherlands, Norway, Poland, Por... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Hypercholesterolemia

United States, Australia, Belgium, Canada, Denmark, Netherlands, New Zealand, Spain
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Hypercholesterolaemia

Belgium, Spain, Germany, Austria, Italy, United States, France, Netherlands, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia (ODYSSEY MONO)

Hypercholesterolemia

United States, Belgium, Finland, Netherlands
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

Hypercholesterolemia

France
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Hypercholesterolemia

United States, Canada, Denmark, France, Hungary, Israel, Korea, Republic of, Russian Federation, South Africa, Ukraine
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Hypercholesterolemia

United States, France, Italy, Israel, United Kingdom, Austria, Canada, Norway
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Hypercholesterolemia

United States, France, Italy, Germany, Spain, Canada, United Kingdom, Australia, Mexico
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin (ODYSSEY-NIPPON)

Hypercholesterolemia

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) (ODYSSEY FH II)

Heterozygous Familial Hypercholesterolemia

United Kingdom, Netherlands, Czech Republic, Norway
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

Hypercholesterolemia

United States, France, Italy, Germany, Spain, Mexico, Canada, United Kingdom, Australia
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY EAST)

Hypercholesterolemia

China, India, Thailand
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Hypercholesterolemia

France, Belgium, Austria, Canada, Czechia, Denmark, Finland, Germany, Greece, Hungary, Poland, Romania, Slovakia, Slovenia, Spain, Switzerland
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
University of California, San Francisco
Massachusetts General Hospital

Recruiting

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) (EPIC-HIV)

Cardiovascular Diseases | HIV Infections | Dyslipidemias

United States
Sanofi
Regeneron Pharmaceuticals

Completed

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (ODYSSEY KIDS)

Hypercholesterolaemia

Norway, Russian Federation, Sweden, South Africa, Czechia, United States, Canada, France, Netherlands, Spain
Sanofi
Regeneron Pharmaceuticals

Completed

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Hypercholesterolaemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia (ODYSSEY J-IVUS)

Hypercholesterolemia | Acute Coronary Syndrome

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Hypercholesterolemia

Slovenia, Taiwan, Russian Federation, Canada, Netherlands, Brazil, Denmark, Mexico, Spain, Turkey
Sanofi
Regeneron Pharmaceuticals

Completed

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Hypercholesterolaemia

Czechia, France, Denmark, Netherlands, Austria, Mexico, Spain, United States, Argentina, Brazil, Bulgaria, Canada, Finland, Hungary, Italy, Lebanon, Norway, Poland, Russian Federation, Slovenia, South Africa, Sweden, Taiwan, Turkey

3

Subscribe